7Baggers

BioNTech SE Quarterly Income Statements Chart

Quarterly
 | 
Annual
 
 Revenue  
 Gross Profit  
 Operating Profit  
 Net Income  
20190331 20190630 20190930 20191231 20200331 20200630 20200930 20201231 20210331 20210630 20210930 20211231 20220331 20220630 20220930 20221231 20230331 20230630 20230930 20231231 -0.560.431.422.413.44.395.386.37Billion

BioNTech SE Quarterly Income Statements Table

Quarterly
 | 
Annual
 
Unit: USD2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 
  revenue1,479,000,000 895,300,000 167,700,000 1,277,000,000 4,278,300,000 3,461,200,000 3,196,500,000 6,374,600,000 5,532,500,000 6,087,300,000 5,308,500,000 2,048,400,000 345,442,000 67,458,000 41,762,000 27,663,000 27,988,000 28,662,000 25,785,000 26,154,000 63,779,000 20,397,000 
  cost of revenue179,100,000 659,700,000 536,300,000 430,000,000 693,300,000 1,094,600,000 1,164,200,000 1,579,900,000 854,700,000 1,471,800,000 1,084,900,000 233,100,000 298,001,000 234,546,000 100,851,000 70,964,000 69,863,000 54,626,000 58,891,000 60,446,000 56,271,000 35,569,000 
  gross profit1,299,900,000 235,600,000 -368,600,000 847,000,000 3,585,000,000 2,366,600,000 2,032,300,000 4,794,700,000 4,677,800,000 4,615,500,000 4,223,600,000 1,815,300,000 47,441,000 -167,088,000 -59,089,000 -43,301,000 -41,875,000 -25,964,000 -33,106,000 -34,292,000 7,508,000 -15,172,000 
  operating expenses                      
  research and development577,800,000 512,382,012 372,578,759 330,650,952 116,000,000 351,109,344 405,798,454 -575,000,000 260,400,000 201,100,000 216,200,000 259,045,000 227,706,000 95,189,000 65,122,000 65,427,000 50,396,000 53,402,000 57,241,000 51,796,000 32,791,000 
  sales and marketing18,000,000 14,400,000 18,100,000 12,200,000 14,600,000 12,800,000 17,800,000 14,300,000 17,900,000 10,500,000 13,300,000 8,700,000 6,704,000 4,268,000 3,054,000 486,000 810,000 670,000 678,000 560,000 1,057,000 769,000 
  general and administrative                      
  total operating expenses131,400,000 136,400,000 122,700,000 119,400,000 122,900,000 141,000,000 130,300,000 90,800,000 128,000,000 66,400,000 46,500,000 38,900,000 28,960,000 23,324,000 17,194,000 14,711,000 6,211,000 10,582,000 13,065,000 8,304,000 7,827,000 6,558,000 
  operating income701,900,000 153,700,000 194,700,000 118,000,000 292,100,000 145,500,000 110,300,000 99,500,000 105,500,000 57,400,000 59,600,000 193,800,000 -189,741,000 19,294,000 21,853,000 15,976,000 11,068,000 10,910,000 14,761,000 9,543,000 9,904,000 6,457,000 
  net income526,200,000 73,100,000 -563,300,000 654,400,000 3,292,900,000 2,387,500,000 2,209,600,000 4,752,700,000 4,699,700,000 4,723,500,000 4,198,400,000 1,662,200,000 244,184,000 -186,382,000 -80,942,000 -59,277,000 -52,943,000 -36,874,000 -47,867,000 -43,835,000 -2,397,000 -21,629,000 

We provide you with 20 years income statements for BioNTech SE stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BioNTech SE stock. Explore the full financial landscape of BioNTech SE stock with our expertly curated income statements.

The information provided in this report about BioNTech SE stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.